Barclays Maintains Overweight on UnitedHealth Group, Lowers Price Target to $603
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Andrew Mok maintains an Overweight rating on UnitedHealth Group but slightly lowers the price target from $604 to $603.
October 22, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays analyst Andrew Mok maintains an Overweight rating on UnitedHealth Group, indicating continued confidence in the stock, but slightly lowers the price target from $604 to $603.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target indicates a minor adjustment in expectations. This is unlikely to have a significant impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100